| [1] |
Gazarian M, Kelly M, Mcphee JR, et al. Off-label use of medicines: consensus recommendations for evaluating appropriateness [J]. Med J Aust, 2006, 185(10): 544-548.
|
| [2] |
杨晓燕，赵静，石晶，等．儿童超说明书用药可视化分析[J]．中国现代应用药学，2015，32(5): 620-625.
|
| [3] |
张伶俐，李幼平，梁毅，等．全球住院儿童超说明书用药现状的系统评价[J]．中国循证医学杂志，2012，12(2): 176-187.
|
| [4] |
张伶俐，李幼平，梁毅，等．全球门诊儿童超说明书用药现状的系统评价[J]．中国循证医学杂志，2012，12(3): 305-313.
|
| [5] |
钟伟金，李佳．共词分析法研究(一)——共词分析的过程与方式[J]．情报杂志，2008，27(5): 70-72.
|
| [6] |
储节旺，郭春侠．EXCEL实现共词分析的方法——以国内图书情报领域知识管理研究为例[J]．情报杂志，2011，30(3): 45-49.
|
| [7] |
王宪磊．信息管理论[M]．北京：社会科学文献出版社，2004：333.
|
| [8] |
李姣，杨晓燕，石晶，等． 基于共词分析法分析我国新生儿输血的研究现状 [J/CD] ．中华妇幼临床医学杂志(电子版)，2018，14(1): 38-43.
|
| [9] |
冯文彬，戴虹，刘敏敏，等．2014－2016年惠州市第二妇幼保健院新生儿重症监护病房用药分析[J]．中国医院用药评价与分析，2017，17(2): 232-234.
|
| [10] |
唐红波，庄太凤，王芳，等．2010－2013年我院新生儿重症监护病房用药分析[J]．儿科药学杂志，2016，22(5): 44-47.
|
| [11] |
李志玲，徐峰，胡文娟，等．新生儿万古霉素低谷浓度和高谷浓度肾毒性的比较[J]．药学服务与研究，2016，16(1): 29-33.
|
| [12] |
Hoppu K. Paediatric clinical pharmacology: at the beginning of a new era [J]. Eur J Clin Pharmacol, 2008, 64(2): 201-205.
|
| [13] |
Agostino R, Pietravalle A. Drugs and newborn [J]. J Matern Fetal Neonatal Med, 2009, 22(Suppl 3): 43-45.
|
| [14] |
Anderson BJ, Holford NHG. Understanding dosing: children are small adults, neonates are immature children [J]. Arch Dis Child, 2013, 98(9): 737-744.
|
| [15] |
Banga V, Mallada A, Kannan S, et al. Awareness about and views of parents on the off-label drug use in children [J]. Int J Risk Saf Med, 2014, 26(2): 61-70.
|
| [16] |
Lenk C, Koch P, Zappel H, et al. Off-label, off-limits? Parental awareness and attitudes towards off-label use in paediatrics [J]. Eur J Pediatr, 2009, 168(12): 1473-1478.
|
| [17] |
Czaja AS, Reiter PD, Schultz ML, et al. Patterns of off-label prescribing in the pediatric intensive care unit and prioritizing future research [J]. J Pediatr Pharmacol Ther, 2015, 20(3): 186-196.
|
| [18] |
中华医学会儿科学分会临床药理学组．中国儿科超说明书用药专家共识[J]．中华儿科杂志，2016，54(2): 101-103.
|
| [19] |
张伶俐，李幼平，曾力楠，等．15国超说明书用药政策的循证评价[J]．中国循证医学杂志，2012，12(4): 426-435.
|
| [20] |
Allegaert K, van den Anker JN. Clinical pharmacology in neonates: small size, huge variability [J]. Neonatology, 2014, 105(4): 344-349.
|
| [21] |
Allegaert K, van de Velde M, van den Anker J. Neonatal clinical pharmacology [J]. Paediatr Anaesth, 2014, 24(1): 30-38.
|
| [22] |
Lenk C, Duttge G. Ethical and legal framework and regulation for off-label use: European perspective [J]. Ther Clin Risk Manag, 2014, 10: 537-546.
|
| [23] |
De Zen L, Marchetti F, Barbi E, et al. Off-label drugs use in pediatric palliative care [J]. Ital J Pediatr. 2018, 44: 144.
|
| [24] |
Corny J, Bailey B, Lebel D, et al. Unlicensed and off-label drug use in paediatrics in a mother-child tertiary care hospital [J]. Paediatr Child Health, 2016, 21(2): 83-87.
|
| [25] |
Gore R, Chugh PK, Tripathi CD, et al. Pediatric off-label and unlicensed drug use and its implications [J]. Curr Clin Pharmacol, 2017, 12(1): 18-25.
|
| [26] |
Oshikoya KA, Wharton GT, Avant D, et al. Serious adverse events associated with off-label use of azithromycin or fentanyl in children in intensive care units: a retrospective chart review [J]. Paediatr Drugs, 2019, 21(1): 47-58.
|
| [27] |
Liu L, Yang HY, Lou Y, et al. Off-label prescriptions in intensive care unit: the Chinese experience [J]. Ther Clin Risk Manag, 2018, 14: 195-202.
|
| [28] |
Landwehr C, Richardson J, Bint L, et al. Cross-sectional survey of off-label and unlicensed prescribing for inpatients at a paediatric teaching hospital in Western Australia [J]. PLoS One, 2019, 14(1): e0210237.
|
| [29] |
Saullo F, Saullo E, Caloiero M, et al. A questionnaire-based study in Calabria on the knowledge of off-label drugs in pediatrics [J]. J Pharmacol Pharmacother, 2013, 4(Suppl1): S51-S54.
|